Clinical Report: Urinary Cytokines and Antimicrobial Peptides as Potential Biomarkers for Recurrent Urinary Tract Infections in Pediatric Patients
Overview
This study identifies distinct urinary immune profiles in pediatric patients with recurrent urinary tract infections (rUTI), highlighting the potential of urinary cytokines and antimicrobial peptides as biomarkers for rUTI classification. The findings suggest that these biomarkers could improve risk stratification and clinical management of rUTI in children.
Background
Recurrent urinary tract infections (rUTI) pose significant clinical challenges, particularly in pediatric populations, leading to increased morbidity and healthcare costs. Current diagnostic tools are inadequate for predicting which patients are at risk for recurrence, necessitating the identification of reliable biological markers. Understanding the role of urinary cytokines and antimicrobial peptides may provide insights into the underlying immune dysregulation associated with rUTI.
Data Highlights
Biomarker
rUTI Group (n=42)
Control Group (n=37)
Beta-defensin 1
Lower
Higher
Cathelicidin
Lower
Higher
Ribonuclease 7
Lower
Higher
Alpha-defensins 1-3
Higher
Lower
Lipocalin 2
Higher
Lower
Secretory leukocyte protease inhibitor
Higher
Lower
IL-1 beta
Elevated
Normal
IL-6
Elevated
Normal
IL-8
Elevated
Normal
TNF-alpha
Elevated
Normal
Key Findings
Participants with rUTI had lower urinary concentrations of beta-defensin 1, cathelicidin, and ribonuclease 7.
Higher concentrations of alpha-defensins 1-3, lipocalin 2, and secretory leukocyte protease inhibitor were observed in the rUTI group.
Cytokine levels, including IL-1 beta, IL-6, IL-8, and TNF-alpha, were significantly elevated in the rUTI group compared to controls.
A multivariable classification model achieved an area under the receiver operating curve of 0.97 for rUTI classification.
The study supports the potential of urinary biomarkers in improving the identification of pediatric patients at risk for rUTI.
Clinical Implications
The distinct urinary immune profiles identified in this study suggest that urinary cytokines and antimicrobial peptides could serve as valuable biomarkers for diagnosing and managing rUTI in pediatric patients. Clinicians may consider integrating these biomarkers into clinical practice to enhance risk stratification and tailor preventive strategies.
Conclusion
The findings indicate that urinary cytokines and antimicrobial peptides are promising candidates for biomarkers in pediatric rUTI, potentially aiding in better clinical decision-making. Further research is warranted to validate these biomarkers in broader clinical settings.
“High-dose intravenous vitamin C administered early after injury did not reduce organ dysfunction or [mortality] and should not be a treatment in severe burns.”
